Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma

Ryan Hickey, Samdeep Mouli, Laura Kulik, Kush Desai, Bartley Thornburg, Daniel Ganger, Talia Baker, Michael Abecassis, Joseph Ralph Kallini, Ahmed Gabr, Vanessa L. Gates, A. B. Benson, Robert J. Lewandowski, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose To assess validity of albumin-bilirubin (ALBI) grade as a predictor of survival in patients undergoing transarterial embolization for hepatocellular carcinoma. Materials and Methods Baseline albumin and bilirubin values of 765 consecutive patients treated with conventional transarterial chemoembolization or yttrium-90 (90Y) radioembolization at a single institution were used to determine liver function according to ALBI grade. Survival outcomes were stratified by ALBI grade using Kaplan-Meier and stratified by Child-Pugh (C-P) class and Barcelona Clinic Liver Cancer (BCLC) stage. Discriminatory ability was assessed by C-index. Results For 428 patients receiving 90Y radioembolization, ALBI grade yielded distinct survival curves (P <.001). When stratified by C-P class and BCLC stage, ALBI grade revealed different survival outcomes for C-P B (P =.001), BCLC A (P <.001), BCLC B (P =.001), and BCLC C (P <.001). When substratified by BCLC stage, ALBI grade was a better discriminator of survival than C-P class (C-index 0.792, 0.763, respectively). For 337 patients receiving transarterial chemoembolization, ALBI grade yielded distinct survival curves (P <.001). When stratified by C-P class and BCLC stage, ALBI grade provided distinct survival curves for C-P B (P =.02), BCLC B (P =.001), and BCLC C (P =.02). When substratified by BCLC stage, ALBI grade was a better discriminator of survival than C-P class (C-index 0.739, 0.735, respectively). Conclusions ALBI grade outperforms C-P class at discriminating survival in patients receiving transarterial chemoembolization or 90Y radioembolization. ALBI grade is also valuable in patients with moderate liver dysfunction and BCLC B disease.

Original languageEnglish (US)
Pages (from-to)795-802
Number of pages8
JournalJournal of Vascular and Interventional Radiology
Volume27
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Bilirubin
Liver Neoplasms
Albumins
Hepatocellular Carcinoma
Survival
Therapeutics
Yttrium
Liver Diseases

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

@article{636e40e097fc4e5c958f689f25108886,
title = "Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma",
abstract = "Purpose To assess validity of albumin-bilirubin (ALBI) grade as a predictor of survival in patients undergoing transarterial embolization for hepatocellular carcinoma. Materials and Methods Baseline albumin and bilirubin values of 765 consecutive patients treated with conventional transarterial chemoembolization or yttrium-90 (90Y) radioembolization at a single institution were used to determine liver function according to ALBI grade. Survival outcomes were stratified by ALBI grade using Kaplan-Meier and stratified by Child-Pugh (C-P) class and Barcelona Clinic Liver Cancer (BCLC) stage. Discriminatory ability was assessed by C-index. Results For 428 patients receiving 90Y radioembolization, ALBI grade yielded distinct survival curves (P <.001). When stratified by C-P class and BCLC stage, ALBI grade revealed different survival outcomes for C-P B (P =.001), BCLC A (P <.001), BCLC B (P =.001), and BCLC C (P <.001). When substratified by BCLC stage, ALBI grade was a better discriminator of survival than C-P class (C-index 0.792, 0.763, respectively). For 337 patients receiving transarterial chemoembolization, ALBI grade yielded distinct survival curves (P <.001). When stratified by C-P class and BCLC stage, ALBI grade provided distinct survival curves for C-P B (P =.02), BCLC B (P =.001), and BCLC C (P =.02). When substratified by BCLC stage, ALBI grade was a better discriminator of survival than C-P class (C-index 0.739, 0.735, respectively). Conclusions ALBI grade outperforms C-P class at discriminating survival in patients receiving transarterial chemoembolization or 90Y radioembolization. ALBI grade is also valuable in patients with moderate liver dysfunction and BCLC B disease.",
author = "Ryan Hickey and Samdeep Mouli and Laura Kulik and Kush Desai and Bartley Thornburg and Daniel Ganger and Talia Baker and Michael Abecassis and {Ralph Kallini}, Joseph and Ahmed Gabr and Gates, {Vanessa L.} and Benson, {A. B.} and Lewandowski, {Robert J.} and Riad Salem",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.jvir.2016.03.005",
language = "English (US)",
volume = "27",
pages = "795--802",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma

AU - Hickey, Ryan

AU - Mouli, Samdeep

AU - Kulik, Laura

AU - Desai, Kush

AU - Thornburg, Bartley

AU - Ganger, Daniel

AU - Baker, Talia

AU - Abecassis, Michael

AU - Ralph Kallini, Joseph

AU - Gabr, Ahmed

AU - Gates, Vanessa L.

AU - Benson, A. B.

AU - Lewandowski, Robert J.

AU - Salem, Riad

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Purpose To assess validity of albumin-bilirubin (ALBI) grade as a predictor of survival in patients undergoing transarterial embolization for hepatocellular carcinoma. Materials and Methods Baseline albumin and bilirubin values of 765 consecutive patients treated with conventional transarterial chemoembolization or yttrium-90 (90Y) radioembolization at a single institution were used to determine liver function according to ALBI grade. Survival outcomes were stratified by ALBI grade using Kaplan-Meier and stratified by Child-Pugh (C-P) class and Barcelona Clinic Liver Cancer (BCLC) stage. Discriminatory ability was assessed by C-index. Results For 428 patients receiving 90Y radioembolization, ALBI grade yielded distinct survival curves (P <.001). When stratified by C-P class and BCLC stage, ALBI grade revealed different survival outcomes for C-P B (P =.001), BCLC A (P <.001), BCLC B (P =.001), and BCLC C (P <.001). When substratified by BCLC stage, ALBI grade was a better discriminator of survival than C-P class (C-index 0.792, 0.763, respectively). For 337 patients receiving transarterial chemoembolization, ALBI grade yielded distinct survival curves (P <.001). When stratified by C-P class and BCLC stage, ALBI grade provided distinct survival curves for C-P B (P =.02), BCLC B (P =.001), and BCLC C (P =.02). When substratified by BCLC stage, ALBI grade was a better discriminator of survival than C-P class (C-index 0.739, 0.735, respectively). Conclusions ALBI grade outperforms C-P class at discriminating survival in patients receiving transarterial chemoembolization or 90Y radioembolization. ALBI grade is also valuable in patients with moderate liver dysfunction and BCLC B disease.

AB - Purpose To assess validity of albumin-bilirubin (ALBI) grade as a predictor of survival in patients undergoing transarterial embolization for hepatocellular carcinoma. Materials and Methods Baseline albumin and bilirubin values of 765 consecutive patients treated with conventional transarterial chemoembolization or yttrium-90 (90Y) radioembolization at a single institution were used to determine liver function according to ALBI grade. Survival outcomes were stratified by ALBI grade using Kaplan-Meier and stratified by Child-Pugh (C-P) class and Barcelona Clinic Liver Cancer (BCLC) stage. Discriminatory ability was assessed by C-index. Results For 428 patients receiving 90Y radioembolization, ALBI grade yielded distinct survival curves (P <.001). When stratified by C-P class and BCLC stage, ALBI grade revealed different survival outcomes for C-P B (P =.001), BCLC A (P <.001), BCLC B (P =.001), and BCLC C (P <.001). When substratified by BCLC stage, ALBI grade was a better discriminator of survival than C-P class (C-index 0.792, 0.763, respectively). For 337 patients receiving transarterial chemoembolization, ALBI grade yielded distinct survival curves (P <.001). When stratified by C-P class and BCLC stage, ALBI grade provided distinct survival curves for C-P B (P =.02), BCLC B (P =.001), and BCLC C (P =.02). When substratified by BCLC stage, ALBI grade was a better discriminator of survival than C-P class (C-index 0.739, 0.735, respectively). Conclusions ALBI grade outperforms C-P class at discriminating survival in patients receiving transarterial chemoembolization or 90Y radioembolization. ALBI grade is also valuable in patients with moderate liver dysfunction and BCLC B disease.

UR - http://www.scopus.com/inward/record.url?scp=84962077673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962077673&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2016.03.005

DO - 10.1016/j.jvir.2016.03.005

M3 - Article

VL - 27

SP - 795

EP - 802

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 6

ER -